Company · Ownership research

Lyell Immunopharma, Inc. LYEL

CIK 0001806952

Form 4 transactions dated Nov 1, 2023 to Nov 15, 2026, as reported to the SEC.

Insider tradingInitial holdingsInstitutional holders

Insider filings on file run through Nov 5, 2026.

Some filings are submitted jointly by several insiders. The SEC form does not apportion the reported figures between them, so results include every joint filer.

Insider purchases & sales

Purchased: $75.45M
Sold: $741.79K

Nov 1, 2023 – Nov 5, 2026
Available records · partial months are marked ·

Insiders in this window

202610 of 27 preview events

Date	Insider	Activity	Trade value (USD)	% of prior holding
Nov 4, 2026	ARCH Venture Fund IX, L.P. · ARCH Venture Fund IX Overage, L.P. · ARCH Venture Partners IX Overage, L.P. · ARCH Venture Partners IX, L.P. · ARCH Venture Partners IX, LLC 10% owner	Purchase	$25.00M 2,321,262 shares bought	Unavailable Indirect holding	▾
Nov 4, 2026	BERNS PAUL L · CRANDELL KEITH · NELSEN ROBERT · BYBEE CLINTON · GILLIS STEVEN · Burow Kristina · ARCH Venture Fund XIII, L.P. · ARCH Venture Partners XIII, LLC · ARCH Venture Partners XIII, L.P. 10% owner	Purchase	$25.00M 2,321,262 shares bought	Unavailable Indirect holding	▾
Oct 12, 2026	Aguirre Jarrad Mattieu Chief Medical Officer	Sale	$3.64K 422 shares sold	2.08% sold Direct holding	▾
Sep 10, 2026	Shook David Chief Medical Officer	Sale	$6.35K 500 shares sold	2.39% sold Direct holding	▾
Aug 21, 2026	Lee Gary K. Chief Scientific Officer	Sale	$22.64K 1,457 shares sold	8.24% sold Direct holding	▾
Aug 21, 2026	Hill Stephen J. Chief Operating Officer	Sale	$15.37K 989 shares sold	5.55% sold Direct holding	▾
Aug 21, 2026	Seely Lynn President and CEO · Director	Sale	$149.01K 9,589 shares sold	13.05% sold Direct holding	▾
Aug 10, 2026	Bulis Veronica Sanchez VP, Corporate Controller	Sale	$8.91K 621 shares sold	4.03% sold Direct holding	▾
Aug 10, 2026	Lee Gary K. Chief Scientific Officer	Sale	$1.88K 131 shares sold	0.74% sold Direct holding	▾
Aug 10, 2026	Hill Stephen J. Chief Operating Officer	Sale	$1.28K 89 shares sold	0.50% sold Direct holding	▾

Showing 27 / 27 record groups in 2026. The complete set is available through the API.

Lyell Immunopharma, Inc. · LYEL

Follow the people behind the trades.

Log in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and reach other datasets through the Akkru API.

Download CSV
Earlier filings
Advanced screening & filtering
API & AI access

Already have an account?

＋ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account. For the year shown, this page lists 27 of 27 purchase / sale groups and 22 of 22 other groups; the totals and the monthly series cover the whole window.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP / CLI.

MCP  https://api.akkrudata.ai/mcp

akkru_insider_transactions
{"action":"list","ticker":"LYEL","transaction_code":["P","S"],"transaction_form_type":"4","page_size":20}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint: https://api.akkrudata.ai/mcp
API / MCP / CLI documentation: /documents
llms.txt: /llms.txt

Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

Non-cancelled, non-derivative purchase (P) and sale (S) rows dated inside the public window, as reported. Share totals are on today's split-adjusted basis. Includes open-market and private transactions. Data after the latest filing is not asserted complete and is not zero-filled. A grouped event shares filing, transaction date, security, code, direction, ownership bucket and source. Derivative groups also match underlying security, exercise price, exercise/expiration dates and footnote references. Reported rows are retained; P/S price lots can be grouped. Post-transaction balances are never summed.